title: Etoposide for epidemic Kaposi's sarcoma: a phase II study.
abstract: Fourteen untreated patients with epidemic Kaposi's sarcoma stages III and IV were treated with etoposide 150 mg/m2 on 3 consecutive days every 4 weeks. No responses were observed. Myelosuppression was severe with white blood count WHO grade 3-4 in nine patients and with platelets WHO grade 3-4 in one patient. Three patients developed opportunistic infections during therapy. It is concluded that etoposide is inactive in epidemic Kaposi's sarcoma.
authors.affiliation: Division of Medical Oncology, University of Amsterdam, The Netherlands.
authors.forename: P J
authors.initials: PJ
authors.lastname: Bakker
authors.forename: S A
authors.initials: SA
authors.lastname: Danner
authors.forename: J M
authors.initials: JM
authors.lastname: Lange
authors.forename: K H
authors.initials: KH
authors.lastname: Veenhof
mesh_terms: D000328:Adult; D004341:Drug Evaluation; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D012514:Sarcoma, Kaposi / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D005047:Etoposide